Orphenadrine

Introduction Overview

Generic Name

Orphenadrine

Brand Name

Norflex, Banflex, Orphenate, Flexoject, Flexon, Mio-Rel, Myolin, Orfro, Norflex Injectable, Antiflex

Dosage Form

Oral tablet, extended-release (100 mg); parenteral injection (60 mg/mL)

Drug Class

Skeletal muscle relaxants

Pharmacokinetics

Absorption:
Orphenadrine is well absorbed from the gastrointestinal tract following oral administration. The extended-release oral tablets allow for a slower and more prolonged absorption phase, maintaining steady plasma drug concentrations. Though specific absorption rates and bioavailability values are not widely reported, clinical use demonstrates effective systemic absorption when administered according to recommended dosing schedules. The onset of action for the oral form is typically within one hour, supporting its use in acute musculoskeletal conditions.

Distribution:
Once absorbed, orphenadrine distributes extensively throughout the body tissues due to its relatively lipophilic nature. It crosses the blood-brain barrier, contributing to its central nervous system activity, which includes muscle relaxation and anticholinergic effects. The volume of distribution is moderate to large; however, precise pharmacokinetic parameters remain limited in literature. Plasma protein binding is variable but believed to be significant, which can affect its distribution profile especially in polypharmacy contexts.

Metabolism:
Orphenadrine undergoes hepatic metabolism primarily via the cytochrome P450 enzyme system, particularly CYP2D6 isoenzymes. The drug is extensively metabolized in the liver to multiple metabolites, some of which may possess pharmacological activity, while others are inactive. Genetic polymorphisms affecting CYP2D6 can influence the metabolism rate, potentially altering therapeutic efficacy and risk of adverse effects. Phase I metabolic reactions include demethylation and hydroxylation, followed by phase II conjugation processes such as glucuronidation.

Elimination:
Renal excretion is the main route of elimination for orphenadrine and its metabolites, with the majority being eliminated in urine as conjugated metabolites. The plasma elimination half-life ranges broadly from approximately 13 to 19 hours, enabling a twice-daily dosing regimen for extended-release formulations. The clearance can vary depending on individual hepatic and renal function status. In patients with impaired liver or kidney function, metabolism and elimination may be reduced, necessitating careful dosing and monitoring.

Dosage Forms

Available Dosage Forms:
- Oral extended-release tablets: 100 mg
- Injectable solution for parenteral use (intravenous or intramuscular): 60 mg/mL

Dosages for Adults and Adolescents:
- Extended-Release Tablets: 100 mg orally twice daily, typically morning and evening doses, for relief of discomfort associated with acute painful musculoskeletal conditions as an adjunct to rest and physical therapy.
- Parenteral Injection: 60 mg administered intravenously (IV) or intramuscularly (IM) every 12 hours as needed, commonly used in hospital settings for rapid relief.

Specific Patient Populations:
- Pediatric use: Safety and effectiveness in patients younger than 18 years have not been established; use is not approved.
- Geriatric considerations: Older adults may be more sensitive to the central nervous system effects and anticholinergic side effects. Dose adjustments and caution are advised.
- Hepatic and renal impairment: Metabolism and excretion may be impaired; dosage modifications should be considered based on clinical response and tolerability.
- Pregnancy and lactation: The safety in pregnancy is not well established; potential risks versus benefits should be carefully evaluated. It is unknown if orphenadrine is excreted in human milk; use caution when administered to nursing mothers.

Mechanism Of Action

Orphenadrine primarily exerts its therapeutic effect as a centrally acting skeletal muscle relaxant. It functions by blocking the central nervous system pathways that are involved in muscle spasm and pain. Orphenadrine has notable anticholinergic properties, which contribute to its muscle relaxant effects by reducing the excitatory cholinergic transmission within the spinal cord and brain.

On a molecular level, orphenadrine acts as a non-selective antagonist of muscarinic acetylcholine receptors, decreasing parasympathetic nervous system activity. This mechanism diminishes muscle spindle overactivity and reduces involuntary muscle contractions. Additionally, orphenadrine's antihistaminic effects help alleviate pain and discomfort caused by muscle injuries.

Furthermore, it possesses mild local anesthetic properties through sodium channel blockade, which contributes to its analgesic action. This multi-modal mechanism of reducing muscle spasm and pain makes orphenadrine effective as an adjunctive treatment in acute musculoskeletal conditions.

Clinically, the central nervous system depressant and anticholinergic activities of orphenadrine contribute to side effects such as sedation, dry mouth, dizziness, and blurred vision. Compared to other muscle relaxants like cyclobenzaprine or methocarbamol, orphenadrine's additional anticholinergic effects make it distinct in its profile. Research supports its efficacy as part of a comprehensive approach including physical therapy and rest for muscle spasm relief.

Pharmacological Actions

Centrally acting skeletal muscle relaxant properties.
Anticholinergic (muscarinic receptor antagonist) effects reducing excitatory cholinergic transmission.
Antihistaminic activity that contributes to analgesic effects.
Mild local anesthetic action via sodium channel blockade.
Reduction of involuntary muscle contractions and muscle spindle activity.
Sedative properties mediated by central nervous system depression.
Analgesic effects for relief of musculoskeletal pain.
Adjunctive role in physical therapy and rehabilitation for muscle conditions.
Influences autonomic nervous system balance with parasympatholytic actions.
May alter neuronal excitability through multiple receptor interactions.
Mitigates muscle spasm secondary to injury or inflammation.
Facilitates improved range of motion by decreasing muscle hypertonicity.

Therapeutic Or Clinical Uses

Treatment of acute painful musculoskeletal conditions including muscle spasm.
As an adjunct to rest and physical therapy for pain relief.
Management of muscle stiffness associated with injury or strain.
Relief of discomfort in skeletal muscle injuries.
Used in rehabilitation to improve muscle relaxation and function.
Short-term therapy for muscle spasticity where appropriate.
Supportive treatment in conditions of muscle hyperactivity.
Occasionally utilized off-label for certain neuromuscular disorders requiring muscle relaxation.
Employed in inpatient settings via parenteral administration for rapid muscle spasm relief.
Adjunct management in postoperative muscle pain where indicated.
Complementary use in conditions with combined pain and muscle rigidity.

Side Or Adverse Effects

Dizziness and light-headedness, potentially impairing alertness.
Drowsiness and sedation, affecting cognitive and motor performance.
Dry mouth due to anticholinergic effects.
Constipation resulting from decreased gastrointestinal motility.
Nausea and vomiting as gastrointestinal adverse reactions.
Weakness and fatigue related to central nervous system depression.
Confusion, agitation, hallucinations, particularly in susceptible patients or overdose.
Urinary retention and difficulty urinating, especially in men with prostatic hypertrophy.
Tachycardia and palpitations due to anticholinergic stimulation of the heart.
Potential allergic reactions such as hives, facial swelling, and difficulty breathing.
Risk of hallucinations or tremors in cases of overdose or sensitivity.
Hypotension or light-headedness associated with vasodilatory effects.
Possible development of dependence or abuse with prolonged use.
Aggravation of pre-existing glaucoma.
Blurred vision and dryness of eyes from anticholinergic activity.

Precautions

Avoid use in patients with known hypersensitivity to orphenadrine.
Cautious use in patients with urinary retention or prostatic hypertrophy.
Exercise caution in patients with glaucoma due to risk of increased intraocular pressure.
Monitor closely in patients with a history of cardiovascular disease or arrhythmias.
Avoid use in individuals with gastrointestinal obstruction, ulcer, or difficulty swallowing.
Use with caution in those with myasthenia gravis due to potential worsening of muscle weakness.
Limit use in patients with history of drug abuse or dependence, as orphenadrine may be habit-forming.
Careful monitoring in elderly patients due to increased risk of sedation and falls.
Adjust dosage for hepatic or renal impairment due to altered metabolism and excretion.
Avoid concomitant use with other central nervous system depressants without medical supervision.
Use in pregnancy only if clearly needed; safety has not been established.
Unknown whether orphenadrine is excreted in breast milk; caution advised during breastfeeding.
Inform patients to avoid alcohol and other sedating agents during therapy.
Educate patients about potential impairment of mental and physical abilities.
Ensure proper storage to prevent accidental ingestion by children or misuse.

Warnings

Contraindicated in patients with urinary retention or significant difficulty urinating.
Should not be used in individuals with enlarged prostate or benign prostatic hyperplasia causing obstruction.
Avoid in glaucoma patients, particularly narrow-angle glaucoma, due to anticholinergic exacerbation.
Not recommended in patients with stomach ulcers or gastrointestinal obstruction.
Contraindicated in patients with difficulty swallowing or gastrointestinal blockage.
Avoid use in myasthenia gravis as it may increase muscular weakness.
May cause CNS depression; impairment in thinking and reactions are possible.
Risk of serious side effects such as confusion, hallucinations, and agitation necessitates caution.
Potential for abuse and dependence; do not share medication and keep secure.
Alcohol consumption with orphenadrine can lead to dangerous side effects including respiratory depression and death.
Use with caution in patients with cardiac arrhythmias or ischemic heart disease.
May cause orthostatic hypotension leading to falls, especially in elderly or debilitated patients.
Immediate medical attention is warranted if signs of allergic reaction or severe adverse effects occur.
Overdose can be life-threatening requiring emergency intervention.
Extended use should be avoided to minimize risk of tolerance and dependency.

Contraindication

Known hypersensitivity or allergy to orphenadrine or any formulation component.
Urinary retention or significant difficulty in urination.
Enlarged prostate or benign prostatic hyperplasia with obstruction.
Glaucoma, particularly narrow-angle glaucoma.
Active stomach ulcer or gastrointestinal obstruction.
Dysphagia or any blockage in the digestive tract.
Myasthenia gravis or other neuromuscular disorders characterized by muscle weakness.
Patients under 18 years of age due to lack of safety data.
Concurrent use with certain monoamine oxidase inhibitors (MAOIs) due to risk of severe interactions (although not explicitly stated but typically applicable in anticholinergic drugs).
Severe hepatic or renal impairment without physician supervision.

Drug Interactions

Concurrent use with other central nervous system depressants (e.g., benzodiazepines, opioids, barbiturates) may enhance sedation and respiratory depression.
Interactions with anticholinergic drugs may potentiate anticholinergic side effects such as dry mouth, constipation, urinary retention, and blurred vision.
Increased risk of tachycardia or arrhythmias when taken with other sympathomimetic agents.
Potential interaction with monoamine oxidase inhibitors (MAOIs) increasing hypertensive crises or CNS effects.
Co-administration with alcohol significantly increases CNS depressive effects and risk of respiratory depression.
Orphenadrine may interfere with medications metabolized by cytochrome P450 2D6, leading to altered plasma levels.
Use with caution when combined with antihistamines due to additive sedation and anticholinergic effects.
Additive effects with tricyclic antidepressants, increasing risk of anticholinergic toxicity.
May reduce efficacy of drugs that require cholinergic activity for therapeutic effects.
Concomitant use with muscle relaxants or anesthetics can exacerbate muscle weakness and sedation.
Potential interaction with medications for Parkinson’s disease due to anticholinergic properties.
Use caution with seizure medications as altered metabolism may affect seizure threshold.
May interfere with heart medications leading to cardiac rhythm disturbances.
Inform healthcare provider of all prescription, over-the-counter, vitamin, and herbal supplements prior to initiation.

Preparations Of The Drug

Oral extended-release tablets containing 100 mg of orphenadrine for twice daily administration.
Parenteral formulations (injectable) providing 60 mg/mL solutions for intravenous or intramuscular injections.
Multiple branded products including Norflex, Banflex, Orphenate, Flexoject, Flexon, Mio-Rel, Myolin, Orfro, Norflex Injectable, and Antiflex.
Extended-release formulations designed to maintain therapeutic plasma concentrations over longer periods.
Available in commercial packaging suitable for outpatient and inpatient use.
Orally administered tablets should be swallowed whole and not crushed or chewed to preserve extended-release properties.
Injection forms provided in sterile vials for hospital or clinical use for rapid onset muscle relaxation.
Formulations meet regulatory requirements for quality, purity, and stability as approved by health authorities.
Prescribed according to patient needs and physician's clinical judgment considering individual contraindications and precautions.
Often supplied with patient information leaflets advising on proper use, storage, and potential side effects.
Manufactured by multiple pharmaceutical companies under different brand names for global distribution.
Must be stored at room temperature, protected from moisture, heat, and light to maintain integrity.
Controlled storage advised due to potential for abuse or misuse; keep out of reach of children.
Dosing units and concentration clearly labeled to avoid medication errors.
Occasionally compounded in special dosage forms when clinically indicated.